ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company' ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...
Icon PLC (ICLR) came out with quarterly earnings of $2.63 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for ...
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) today ...
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Investors in ICON plc (ICLR) saw the price of their shares drop about 49% during trading on February 12, 2026, after the company disclosed its ...
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, ...
Orbis Investment Management released its Q4 2025 investor letter for “Orbis SICAV International Equity Fund”. The Strategy reported a positive year in 2025, with returns driven more by stock-specific ...
We recently published 10 Market Beasts Leaving Wall Street in the Dust. ICON PLC (NASDAQ:ICLR) was one of the best performers on Friday. ICON grew its share prices by 16.13 percent on Friday to finish ...
Partnership will integrate ICON’s clinical trial technology with Advarra’s purpose-built system for research sites, embedded across a broad, deeply established global network. Partnership will reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results